Investors Unite in Class Action against ADMA Biologics for Securities Violations

ADMA Biologics, Inc., operating under the NASDAQ symbol ADMA, is currently facing a class action lawsuit related to securities law violations. This legal action has been brought to the forefront by the DJS Law Group, which aims to advocate for the rights of investors who may have suffered losses due to alleged wrongdoing by the Company.

Background of the Case

The lawsuit specifically targets ADMA's purported violations of sections 10(b) and 20(a) of the Securities Exchange Act of 1934, along with Rule 10b-5 enforced by the U.S. Securities and Exchange Commission. These provisions are designed to protect investors by prohibiting fraudulent activities in connection with the purchase or sale of securities.

The complaint states that the Company has engaged in misleading practices that misrepresented its financial performance and operational activities. During the class period starting from August 9, 2024, to March 25, 2026, ADMA is accused of failing to disclose critical information regarding a related party transaction and artificially inflating its sales figures to simulate an increase in sales activity. These actions have led to public statements that the lawsuit claims were both false and materially misleading, ultimately harming shareholders who invested based on the Company’s reports.

Class Action Details

The deadline for shareholders wishing to join this class action as lead plaintiffs is August 10, 2026. The DJS Law Group encourages anyone who purchased shares of ADMA during the designated class period to reach out, even if they are not looking to become the lead plaintiff. Participation in the class action does not require this status, but it may entitle investors to possible recovery for their losses.

This case comes at a time when shareholder activism is becoming increasingly prominent in the finance sector. Many investors are recognizing their rights and are willing to take legal action when they feel misled or wronged by corporate entities.

Why Choose DJS Law Group?

DJS Law Group is known for its dedicated focus on enhancing returns for investors through strategic legal advocacy. They specialize in handling class action lawsuits related to securities, offering investors robust support as they navigate complex legal landscapes. The firm claims that the litigation pursued on behalf of their clients is considered a valuable asset that requires serious attention.

The attorneys at DJS Law Group have emphasized their commitment to balanced counseling and aggressive litigation strategies. They have built a reputation for representing some of the world's largest hedge funds and alternative asset managers, showcasing their capability in handling significant and multifaceted financial disputes.

Take Action

For shareholders who believe they have been impacted by ADMA's actions, the message from DJS Law Group is clear: do not hesitate to contact them to explore your legal options. Participating in this lawsuit may offer a pathway to recover losses suffered during the specified class period.

As this case progresses, it will undoubtedly shed more light on the obligations of companies to their investors and the importance of transparency in financial reporting. Investors are reminded to stay informed about their rights and consider seeking counsel if they believe they may have been affected by potential securities law violations associated with ADMA Biologics.

In conclusion, this class action lawsuit serves as a crucial reminder of the importance of investor vigilance and the legal recourse available to address possible misconduct within corporate environments.